Vutrisiran – Medxy AI

Consistent Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis Amidst Concomitant Disease-Modifying Therapies

By MedXY 09/02/2026

The HELIOS-B trial demonstrates that vutrisiran significantly reduces mortality and cardiovascular events in ATTR-CM patients, with its efficacy unaffected by concurrent use of tafamidis or heart failure medications, supporting its broad therapeutic applicability.

Cardiology news

Vutrisiran and Tafamidis in Transthyretin Amyloidosis Cardiomyopathy: Evaluating Combination Therapy Insights from HELIOS-B

By MedXY 09/01/2026

The HELIOS-B trial showed vutrisiran improves survival and cardiac outcomes in transthyretin amyloidosis with cardiomyopathy, with consistent benefits regardless of baseline tafamidis use, supporting further evaluation of combination therapy.

Cardiology Clinical Updates news

Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Insights from the HELIOS-B Trial

By MedXY 08/28/2026

This review synthesizes evidence on the prevalence and prognostic value of right ventricular dysfunction in ATTR-CM and the therapeutic impact of vutrisiran on RV function from the HELIOS-B trial, underscoring RV free wall strain as a key biomarker and treatment target.

Cardiology news

Left Atrial Dysfunction and Vutrisiran Efficacy in Transthyretin Amyloid Cardiomyopathy: Insights from the HELIOS-B Trial

By MedXY 08/21/2026

This article reviews the prognostic role of left atrial dysfunction in transthyretin amyloid cardiomyopathy and evaluates vutrisiran’s impact on atrial function and clinical outcomes based on a secondary analysis of the HELIOS-B phase 3 trial.

Cardiology Clinical Updates news Radiology

Vutrisiran Treatment and Cardiovascular MRI-Detected Changes in Cardiac Structure, Function, and Amyloid Burden in ATTR-CM

By MedXY 08/13/2026

Vutrisiran, an RNA interference therapeutic, significantly improves cardiac function, reduces amyloid burden, and attenuates disease progression in transthyretin amyloid cardiomyopathy as revealed by multiparametric cardiovascular MRI and corroborated by echocardiographic findings.

Cardiology news

Vutrisiran Redefines the Therapeutic Landscape for Transthyretin Amyloidosis with Cardiomyopathy: Comprehensive Insights from the HELIOS-B Trial

By MedXY 12/25/2025

The HELIOS-B trial demonstrates that vutrisiran significantly improves clinical outcomes, stabilizes cardiac biomarkers, preserves cardiac structure, and enhances the quality of life in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

Cardiology news Specialties

Vutrisiran’s Impact on Cardiac Function and Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights from HELIOS-B

By MedXY 08/17/2025

Vutrisiran improves cardiac structure, function, and biomarkers, reducing mortality and cardiovascular events in transthyretin amyloid cardiomyopathy over 30 months.